Otsuka adds Phase 3 data to Voyxact’s IgA nephropathy case
CURRENT FULL VERSION: Otsuka is extending the clinical story around Voyxact after reporting additional Phase 3 VISIONARY data in IgA nephropathy, a program that already led to FDA accelerated approval in the U.S. on November 25, 2025, for reducing proteinuria in adults with primary IgA nephropathy at risk for disease progression. The drug, sibeprenlimab-szsi, is marketed as Voyxact and works by blocking APRIL, a cytokine involved upstream in the production of galactose-deficient IgA1, a key driver in IgAN pathogenesis. The update also comes as Otsuka is broadening its overall pipeline through business development, including an agreement via Otsuka America to acquire Transcend Therapeutics for about $1.225 billion. (otsuka-us.com; PharmaShots)
The backdrop here is a fast-moving IgAN treatment landscape, where regulators have increasingly accepted proteinuria as an early surrogate endpoint while requiring longer follow-up on kidney function. In VISIONARY, Otsuka enrolled 530 adults in an active, not recruiting, randomized, double-blind, placebo-controlled study on top of maximally tolerated standard of care, including ACE inhibitor and/or ARB therapy, with optional background SGLT2 inhibitor use. The trial’s primary endpoint is 24-hour urine protein-to-creatinine ratio at nine months, while the key secondary endpoint is annualized eGFR slope over roughly 24 months. (clinicaltrials.gov)
The initial interim dataset was strong enough to support regulatory action. Otsuka reported that Voyxact achieved a significant placebo-adjusted treatment effect of 51% on proteinuria at nine months, with a 50% reduction from baseline in the active arm versus a 2% increase with placebo in the interim analysis population of 320 patients. In November 2025, the company said a 12-month interim analysis presented at ASN Kidney Week and published in the New England Journal of Medicine showed a 54.3% placebo-adjusted reduction in geometric mean 24-hour UPCR. The FDA’s approval notice also made clear that continued approval may depend on confirmation that Voyxact slows kidney function decline in the ongoing VISIONARY trial. (otsuka-us.com)
Mechanistically, Voyxact stands out because it targets APRIL rather than the hemodynamic pathways addressed by standard supportive care. FDA review documents describe primary IgAN as a serious kidney disease and note that sibeprenlimab is intended to reduce levels of galactose-deficient IgA1 implicated in disease pathogenesis. That upstream approach has helped position APRIL blockade as one of the more closely watched strategies in immune-mediated kidney disease, especially as multiple developers pursue adjacent BAFF/APRIL programs. (accessdata.fda.gov)
Industry and expert commentary has generally framed the VISIONARY results as clinically meaningful, but still incomplete. ASN’s Kidney Week press materials said the data suggest sibeprenlimab may have a strong protective effect on kidney function, while Kidney News described the agent as poised to reshape the IgAN landscape if the longer-term data hold. That cautious optimism matters: nephrology has seen several programs win attention on proteinuria before the field had mature evidence on preservation of kidney function. In parallel, Otsuka is also signaling a willingness to spend heavily to build other parts of its pipeline. The planned Transcend acquisition includes $700 million upfront and up to about $525 million in sales milestones, with closing expected in Q2 2026. The deal would add TSND-201, or methylone, which is advancing toward Phase 3 for PTSD with U.S. patient recruitment underway, and it also brings Transcend’s work on novel prodrugs intended to improve efficacy, safety, and tolerability, with one candidate selected and nonclinical studies underway toward an FDA IND filing. (asn-online.org; PharmaShots)
Why it matters: For veterinary professionals, this is not a companion-animal therapeutic development, but it is relevant as a window into how renal drug development is evolving. The Voyxact story combines biomarker-driven trial design, immune-pathway targeting, and accelerated approval tied to confirmatory follow-up, themes that increasingly influence translational research beyond human nephrology. It also highlights the commercial and clinical pressure to move earlier in chronic kidney disease, before irreversible damage accumulates, an idea that resonates across species even when the underlying diseases differ. Otsuka’s simultaneous push in neuropsychiatry is not directly relevant to veterinary practice, but it does provide context on how large biopharma companies are allocating capital across late-stage and specialty programs. (clinicaltrials.gov; PharmaShots)
What to watch: The biggest next milestone is the confirmatory eGFR analysis from VISIONARY, with ClinicalTrials.gov listing primary completion and study completion for December 30, 2026. If the kidney function data are positive, Voyxact’s accelerated approval would be on stronger footing and the drug’s role in IgAN could expand; if not, regulators and clinicians will have to revisit how much weight to place on the proteinuria signal alone. On the corporate side, Otsuka’s expected Q2 2026 close of the Transcend deal will be another sign of how aggressively it is trying to deepen its late-stage pipeline. (clinicaltrials.gov; PharmaShots)